HERON THERAPEUTICS, INC. /DE/

For the period ended Jun 30, 2025. Filed Aug 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 8, 2025

HRTX$0.37+0.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income

(In thousands, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Revenues:
Net product sales	$37,200	$36,024	$76,103	$70,694
Cost of product sales	9,857	10,518	18,314	18,962
Gross profit	27,343	25,506	57,789	51,732
Operating expenses:
Research and development	2,934	4,432	5,213	9,040
General and administrative	14,471	13,905	27,173	28,879
Sales and marketing	11,575	13,614	23,886	25,056
Total operating expenses	28,980	31,951	56,272	62,975
(Loss) income from operations	(1,637)	(6,445)	1,517	(11,243)
Other expense, net	(744)	(2,790)	(1,263)	(1,152)
Net (loss) income	(2,381)	(9,235)	254	(12,395)
Other comprehensive loss:
Unrealized loss on short-term investments	(2)	(2)	(14)	(21)
Comprehensive (loss) income	$(2,383)	$(9,237)	$240	$(12,416)
Basic net (loss) income per share	$(0.02)	$(0.06)	$0.00	$(0.08)
Diluted net (loss) income per share	$(0.02)	$(0.06)	$0.00	$(0.08)
Weighted average common shares outstanding, basic	154,020	152,305	153,804	151,900
Weighted average common shares outstanding, diluted	154,020	152,305	197,751	151,900

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.